Cometriq: new protein kinase inhibitor for thyroid carcinoma

Cometriq (cabozantinib) is indicated for the treatment of adults with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.

Medullary thyroid cancer is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. SCIENCE PHOTO LIBRARY
Medullary thyroid cancer is a rare malignancy originating from calcitonin-producing parafollicular C cells of the thyroid. SCIENCE PHOTO LIBRARY

Cabozantinib inhibits the activity of tyrosine kinases (including RET, MET and VEGF receptors) involved in cellular function and pathologic processes such as oncogenesis, metastasis, tumour angiogenesis and maintenance of the tumour microenvironment.

Survival benefit

The safety and efficacy of cabozantinib were established in a randomised, double-blind trial involving 330 patients with unresectable locally advanced or metastatic medullary thyroid cancer who had radiographic evidence of disease progression within 14 months before study entry.

Patients who received cabozantinib 140mg once daily survived for a median of 11.2 months without tumour progression compared with a median of 4 months in the placebo group (HR 0.28, 95% CI 0.19-0.40, p<0.001). Prior therapy with tyrosine kinase inhibitors had no influence on progression-free survival rates.

The overall response rate in cabozantinib-treated patients was 28%, compared with 0% in those who received placebo (p<0.0001). Estimated responses lasted a median of 14.6 months in the cabozantinib arm (95% CI 11.1-17.5 months).

Safety

The most commonly reported serious adverse reactions of cabozantinib were pneumonia, mucosal inflammation, hypocalcaemia, dysphagia, dehydration, pulmonary embolism and hypertension.

View Cometriq drug record

Further information: Swedish Orphan Biovitrum

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.